#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Current perspectives on the aetiology of tall stature in children and adolescents (2): Non-syndromic tall stature


Authors: Adamovičová Kateřina;  Plachý Lukáš;  Lebl Jan;  Koloušková Stanislava;  Průhová Štěpánka
Authors place of work: 2. lékařská fakulta Univerzity ;  Karlovy a Fakultní nemocnice, v Motole ;  Pediatrická klinika
Published in the journal: Čes-slov Pediat 2022; 77 (Supplementum 3): 18-23.
Category: Comprehensive Report
doi: https://doi.org/10.55095/CSPediatrie2022/054

Summary

Non-syndromic tall stature can be caused by growth hormone overproduction, hyperthyroidism, obesity, hypogonadism, precocious puberty or as constitutional growth acceleration. There are conditions caused by a genetic cause as well such as non-sydromic tall stature, typically familial tall stature or, more rarely, pituitary gigantism, which includes X-linked acrogigantism (XLAG). Tall stature can rarely occur in neurofibromatosis type I or in glucocorticoid resistance. After excluding the common endocrinopathies the patients are, in clinical practice, assigned as “familial tall stature” or “constitutional growth acceleration”. Recently, there have been findings showing that non-syndromic tall stature can be caused by a monogenic cause, which can only be found by detailed genetic testing with precise clinical-genetic evaluation. 

Keywords:

tall stature – growth hormone overproduction – FIPA – XLAG – familial tall stature


Zdroje
  1. Meazza C, Gertosio C, Giacchero R, et al. Tall stature: a difficult diagnosis? Ital J Pediatr 2017;43(1):66.
  2. Albuquerque E, Scalco RC, Jorge A. Management of endocrine disease: Diagnostic and therapeutic approach of tall stature. Eur J Endocrinol 2017; 176(6): 339–353.
  3. Leung AKC, Leung AAC, Hon KL. Tall stature in children. Adv Pediatr 2019; 66: 161–176.
  4. Wei C, Gregory JW. Physiology of normal growth. Paediatrics Child Health 2009; 19(5): 236–240.
  5. Baron J, Sävendahl L, De Luca F, et al. Short and tall stature: a new paradigm emerges. Nat Rev Endocrinol 2015; 11(12): 735–746.
  6. Lazarus JE, Hegde A, Andrade AC, et al. Fibroblast growth factor expression in the postnatal growth plate. Bone 2007; 40(3): 577–586.
  7. Liu Z, Lavine KJ, Hung IH, Ornitz DM. FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev Biol 2007; 302(1): 80–91.
  8. Mancilla EE, De Luca F, Uyeda JA, et al. Effects of fibroblast growth factor-2 on longitudinal bone growth. Endocrinology 1998; 139(6): 2900–2904.
  9. Hung IH, Yu K, Lavine KJ, Ornitz DM. FGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopod. Developmen Biol 2007; 307(2): 300–313.
  10. Nilsson O, Parker EA, Hegde A, et al. Gradients in bone morphogenetic protein–related gene expression across the growth plate. J Endocrinol 2007; 193(1): 75–84.
  11. De Luca F, Barnes KM, Uyeda JA, et al. Regulation of growth plate chondrogenesis by bone morphogenetic protein-2. Endocrinology 2001; 142(1): 430–436.
  12. Hannema SE, van Duyvenvoorde HA, Premsler T, et al. An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities. J Clin Endocrinol Metab 2013; 98(12): 1988–1998.
  13. Miura K, Kim OH, Lee HR, et al. Overgrowth syndrome associated with a gain–of–function mutation of the natriuretic peptide receptor 2 (NPR2) gene. Am J Med Genet A 2014; 164 A (1): 156–163.
  14. Chan Y, Holmen OL, Dauber A, et al. Common variants show predicted polygenic effects on height in the tails of the distribution, except in extremely short individuals. PLoS Genet 2011; 7(12): e1002439.
  15. Plachy L, Dusatkova P, Maratova K, et al. Familial short stature—a novel phenotype of growth plate collagenopathies. J Clin Endocrinol Metabolism 2021; 106(6): 1742–1749.
  16. Corredor B, Dattani M, Gertosio C, Bozzola M. Tall stature: a challenge for clinicians. Curr Pediatr Rev 2019; 15(1): 10–21.
  17. Vasilev V, Daly AF, Trivellin G, et al. Hereditary endocrine tumours: current state-of-the-art and research opportunities: The role of AIP and GPR101 in familial isolated pituitary adenomas (FIPA ). Endocr Rel Cancer 2020; 27(8): T77–T86.
  18. Beckers A, Petrossians P, Hanson J, Daly AF. The causes and consequences of pituitary gigantism. Nat Rev Endocrinol 2018; 14(12): 705–720.
  19. Cannavo S, Ragonese M, Puglisi S, et al. Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted areas. J Clin Endocrinol Metab 2016; 101(4): 1872–1879.
  20. Daly AF, Lysy PA , Desfilles C, et al. GHRH excess and blockade in X–LAG syndrome. Endocr Rel Cancer 2016; 23(3): 161–170.
  21. Beckers A, Lodish MB, Trivellin G, et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Rel Cancer 2015; 22(3): 353–367.
  22. Pagani S, Radetti G, Meazza C, Bozzola M. Analysis of growth hormone receptor gene expression in tall and short stature children. J Pediatr Endocrinol Metab 2017; 30(4): 427–430.
  23. Carmi D, Shohat M, Metzker A, Dickerman Z. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics 1999; 103(6): 1257–1262.
  24. Meimaridou E, Hughes CR, Kowalczyk J, et al. Familial glucocorticoid deficiency: New genes and mechanisms. Mol Cell Endocrinol. 2013; 371(1–2): 195–200.
  25. Savage MO, Lebrethon MC, Blair JC, et al. Growth abnormalities associated with adrenal disorders and their management. Horm Res 2001; 56 Suppl 1: 19–23.
Štítky
Neonatology Paediatrics General practitioner for children and adolescents

Článok vyšiel v časopise

Czech-Slovak Pediatrics

Číslo Supplementum 3

2022 Číslo Supplementum 3
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#